MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 to 22 in Boston. Over 1,100 attendees are expected. The venue is the Westin ...

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity. Johnson & Johnson announced that the US Food and Drug ...

Building on prior Ophthalmology Times coverage examining how ophthalmic drug shortages are both more frequent and longer-lasting than the national average, Ian Pitha, MD, PhD, an ophthalmologist at ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

In late 2025, a group of researchers that included Maria Emfietzoglou, MD, and Victor S.M.C. Correa, MD, published a paper titled, “Inner Plexiform Layer Substrata Are Discernible with Commercial OCT ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...

Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.